\-\ Texto\\:\\ \ \(0\)\
\-\ tsi\\ 279\\ h\\ \\(\\<125\\)\ \(0\)\
\-\ thyrotro\\ bn\\ inh\\ 78\\.7\\ h\\ \\(\\<16\\)\ \(0\)\
\-\ tsh\\ 1\\.98\\ \\(0\\.27\\ \\‚\\Ä\\ì\\ 4\\.2\\)\ \(0\)\
\-\ ft4\\ 1\\.25\\ \\(1\\.01\\ \\‚\\Ä\\ì\\ 1\\.79\\)\ \(0\)\
\-\ per\\ endocrine\ \(0\)\
\-\ enlargement\\ of\\ the\\ inferior\\,\\ medial\\ and\\ superior\\ recti\\ with\\ sparing\\ of\\ the\\ tendons\\.\\ \\ symmetric\\ bilateral\\ prominent\\ proptosis\\.\\ \\ optic\\ nerves\\ are\\ normal\\.\\ \\ no\\ retrobulbar\\ mass\\ or\\ fatty\\ infiltration\\.\\ \\ prominent\\ maxillary\\ sinus\\ mucosal\\ thickening\\ with\\ extension\\ into\\ the\\ ethmoid\\ air\\ cells\\ and\\ frontal\\ sinuses\\ with\\ obstruction\\ of\\ the\\ infundibula\\.\ \(0\)\
\-\ graves\\ ophthalmopathy\ \(0\)\
\-\ thyroid\\ opthalmopathy\\,\\ acromegaly\\,\\ pseudotumor\\,\\ infection\\,\\ plasma\\ cell\\ granuloma\\,\\ sarcoid\\,\\ tb\\,\\ lymphoma\\,\\ leukemia\\,\\ rhabdomyosarcoma\\,\\ metastatic\\,\\ carotid\\ cavernous\\ fistula\\,\\ extradural\\ arteriovenous\\ fistula\\,\\ amyloid\ \(0\)\
\-\ painless\\ proptosis\ \(4\)\
\-\ top\\ considerations\\ being\\ pseudotumor\\ and\\ graves\\.\ \(0\)\
\-\ orbital\\ pseudotumor\\:\\ unilateral\\ 85\\%\\,\\ involves\\ tendon\\,\\ ill\\ defined\\ margins\\,\\ inflammation\\ of\\ fat\\,\\ enlarged\\ lacrimal\\ gland\\,\\ good\\ response\\ to\\ steroids\\,\\ painful\\ and\\ therefore\\ not\\ the\\ diagnosis\\.\ \(0\)\
\-\ graves\\ disease\\:\\ \ \(0\)\
\-\ graves\\‚\\Ä\\ô\\ ophthalmopathy\\ develops\\ in\\ most\\ patients\\ with\\ graves\\‚\\Ä\\ô\\ disease\\,\\ and\\ is\\ the\\ most\\ common\\ orbital\\ disorder\\ in\\ us\\ population\\ causing\\ most\\ unilateral\\ and\\ bilateral\\ exophthalmos\\ in\\ adults\\,\\ 80\\%\\ of\\ bilateral\\,\\ 15\\-28\\%\\ of\\ unilateral\\ cases\\.\\ orbital\\ disease\\ usually\\ follows\\ hormonal\\ changes\\ but\\ may\\ be\\ first\\ sign\\ of\\ graves\\.\\ \\ it\\ is\\ more\\ common\\ in\\ females\\ but\\ worse\\ clinical\\ course\\ in\\ males\\ and\\ older\\ age\\.\ \(0\)\
\-\ painless\\ proptosis\\;\\ double\\ vision\\,\\ and\\ periorbital\\ swelling\\ and\\ chemosis\\ are\\ common\\.\ \(0\)\
\-\ werner\\‚\\Ä\\ôs\\ modified\\ staging\\ system\\ for\\ thyroid\\ orbitopathy\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade1\\:\\ asymptomatic\\,\\ lid\\ retraction\\,\\ stare\\,\\ lid\\ lag\\ \\(spasm\\ of\\ upper\\ lid\\ due\\ to\\ thyrotoxicosis\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 2\\:\\ symptomatic\\ eyelid\\ retraction\\,\\ soft\\ tissue\\ involvement\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 3\\:\\ proptosis\\ as\\ determined\\ by\\ exophthalmometer\\ measurement\\ \\>22mm\\,\\ without\\ diplopia\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 4\\:\\ proptosis\\ \\>\\ 22mm\\ with\\ diplopia\\,\\ extraocular\\ muscle\\ involvement\\;\\ affects\\ muscles\\ at\\ midpoint\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 5\\:\\ corneal\\ involvement\\ \\(ulceration\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 6\\:\\ optic\\ nerve\\ involvement\\:\\ loss\\ of\\ vision\ \(0\)\
\-\ it\\ resolves\\ spontaneously\\ in\\ more\\ than\\ 90\\%\\ of\\ cases\\ with\\ the\\ remaining\\ developing\\ eye\\ complications\\.\\ \\ treatment\\:\\ head\\ elevation\\ at\\ night\\,\\ lubricating\\ eyedrops\\,\\ ointments\\&\\#8594\\;\\ steroids\\/radiation\\ therapy\\ \\&\\#8594\\;\\ immunosuppressives\\,\\ surgery\\.\\ \ \(0\)\
\-\ pathophysiology\\:\\ enlargement\\ of\\ eom\\:\\ 3\\ basic\\ mechanisms\\:\\ infiltration\\ by\\ abnormal\\ cells\\,\\ deposition\\ of\\ abnormal\\ material\\ \\(amyloid\\,\\ mucopolysaccharides\\)\\,\\ or\\ edema\\ from\\ vascular\\ congestion\\.\\ degree\\ of\\ orbital\\ involvement\\ does\\ not\\ correlate\\ with\\ degree\\ of\\ thyroid\\ dysfunction\\ or\\ levels\\ of\\ circulating\\ autoantibodies\\.\ \(0\)\
\-\ \\	inflammatory\\ leukocytic\\ infiltration\\ with\\ edema\\ and\\ deposition\\ of\\ mucopolysaccharides\\ in\\ the\\ orbital\\ contents\\,\\ predominantly\\ involving\\ the\\ eoms\\ and\\ retrobulbar\\ fat\\.\\ \\ thought\\ to\\ be\\ autoimmune\\ due\\ to\\ cross\\-reactivity\\ between\\ eye\\ muscle\\ and\\ thyroid\\ autoantigens\\.\\ \\ autoantibodies\\ implicated\\ include\\:\\ long\\ acting\\ thyroid\\ stimulating\\ factor\\ \\(lats\\)\\ and\\ thyroid\\ stimulating\\ immunoglobulins\\ \\(tsi\\)\\,\\ and\\ circulating\\ autoantibodies\\ against\\ a\\ human\\ eye\\ muscle\\ soluble\\ antigen\\.\ \(0\)\
\-\ \\	early\\ acute\\ inflammatory\\ stage\\ involves\\ deposition\\ of\\ hygroscopic\\ mucopolysaccharides\\ and\\ glycoproteins\\ with\\ infiltration\\ by\\ inflammatory\\ cells\\.\\ \\ \ \(0\)\
\-\ \\	disease\\ progression\\ results\\ in\\ replacement\\ by\\ collagenous\\ tissue\\,\\ necrosis\\ of\\ muscle\\ fibers\\ and\\ fatty\\ degeneration\\,\\ which\\ results\\ from\\ chronic\\ increase\\ in\\ orbital\\ pressure\\ leading\\ to\\ ischemia\\,\\ edema\\,\\ and\\ fibrosis\\ of\\ muscles\\.\\ \\ the\\ fibrotic\\ phase\\ is\\ irreversible\\.\\ \\ \ \(0\)\
\-\ \\	proptosis\\:\\ enlargement\\ of\\ eoms\\,\\ edema\\,\\ increased\\ volume\\ of\\ retrobulbar\\ fat\\,\\ vascular\\ congestion\\,\\ and\\ corneal\\ ulcers\\.\\ degree\\ of\\ proptosis\\ is\\ measured\\ in\\ axial\\ plane\\ at\\ level\\ of\\ lens\\ from\\ interzygomatic\\ line\\ to\\ anterior\\ margin\\ of\\ globe\\.\ \(0\)\
\-\ \\	compression\\ on\\ optic\\ nerve\\ may\\ result\\ in\\ ischemia\\ and\\ optic\\ neuropathy\\.\ \(0\)\
\-\ imaging\\:\ \(4\)\
\-\ muscle\\ involvement\\:\\ most\\ common\\ structures\\ affected\\,\\ most\\ often\\ affects\\ the\\ medial\\ and\\ inferior\\ recti\\ \\‚\\Ä\\úi\\‚\\Ä\\ôm\\ slow\\‚\\Ä\\ù\\ normal\\ recti\\ muscle\\ belly\\ diameter\\ is\\ 3\\ mm\\.\\ often\\ bilateral\\,\\ symmetrical\\ 85\\%\\.\\ isolated\\ involvement\\ of\\ single\\ muscle\\ 10\\%\\ usually\\ superior\\ rectus\\ and\\ levator\\ palpebrae\\ complex\\.\\ classically\\ swelling\\ is\\ maximal\\ in\\ belly\\,\\ sparing\\ tendinous\\ attachments\\,\\ and\\ margins\\ of\\ muscles\\ are\\ smooth\\.\\ \\ \ \(0\)\
\-\ other\\ imaging\\ findings\\ are\\ increased\\ amount\\ of\\ retro\\-ocular\\ fat\\,\\ stranding\\ of\\ the\\ intraconal\\ fat\\,\\ enlarged\\ lacrimal\\ gland\\,\\ stretching\\ of\\ the\\ optic\\ nerve\\,\\ and\\ increased\\ diameter\\ of\\ optic\\ nerve\\ sheath\\ due\\ to\\ csf\\ trapping\\ in\\ subarachnoid\\ space\\.\ \(0\)\
\-\ mr\\:\\ muscles\\ may\\ be\\ thick\\ and\\ of\\ high\\ signal\\ intensity\\ on\\ t2wi\\,\\ reflecting\\ edema\\.\\ \\ tram\\ track\\ sign\\ on\\ t2w\\ is\\ suspicious\\ for\\ optic\\ nerve\\ compression\\ and\\ represents\\ dilatation\\ of\\ subarachnoid\\ space\\ surrounding\\ the\\ optic\\ nerve\\ \\(ddx\\ for\\ this\\ sign\\:\\ increased\\ intracranial\\ pressure\\ and\\ pseudotumor\\ cerebri\\)\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ proptosis\\:\\ 0\\.042611313894035246\ \(0\)\
\-\ graves\\:\\ 0\\.04094221317219468\ \(0\)\
\-\ optic\\:\\ 0\\.04036434713882475\ \(0\)\
\-\ recti\\:\\ 0\\.03108050220691283\ \(0\)\
\-\ mucopolysaccharides\\:\\ 0\\.03108050220691283\ \(0\)\
\-\ autoantibodies\\:\\ 0\\.03108050220691283\ \(0\)\
\-\ orbital\\:\\ 0\\.031020493539556698\ \(0\)\
\-\ involvement\\:\\ 0\\.027963738005605504\ \(0\)\
\-\ muscle\\:\\ 0\\.027404600298449506\ \(0\)\
\-\ \\:\\:\\ 0\\.027391864163039074\ \(0\)\
\-\ thyroid\\:\\ 0\\.026803411568301357\ \(0\)\
\-\ retrobulbar\\:\\ 0\\.025775804396505085\ \(0\)\
\-\ pseudotumor\\:\\ 0\\.025226109250299018\ \(0\)\
\-\ infiltration\\:\\ 0\\.02375834357452462\ \(0\)\
\-\ lid\\:\\ 0\\.023634417452874642\ \(0\)\
\-\ nerve\\:\\ 0\\.023563363212913056\ \(0\)\
\-\ 22mm\\:\\ 0\\.0224885674080778\ \(0\)\
\-\ 8594\\:\\ 0\\.0224885674080778\ \(0\)\
\-\ grade\\:\\ 0\\.020757887710146496\ \(0\)\
\-\ muscles\\:\\ 0\\.019912569072604316\ \(0\)\
\-\ tsi\\:\\ 0\\.0196859850390265\ \(0\)\
\-\ \\,\\:\\ 0\\.018991139800319905\ \(0\)\
\-\ eoms\\:\\ 0\\.018382858447786726\ \(0\)\
\-\ deposition\\:\\ 0\\.01826199166887225\ \(0\)\
\-\ circulating\\:\\ 0\\.017524510905385673\ \(0\)\
\-\ belly\\:\\ 0\\.0168834026699752\ \(0\)\
\-\ stimulating\\:\\ 0\\.016614625844317478\ \(0\)\
\-\ fat\\:\\ 0\\.016574695936745112\ \(0\)\
\-\ corneal\\:\\ 0\\.016371487630530937\ \(0\)\
\-\ unilateral\\:\\ 0\\.016227579510700696\ \(0\)\
\-\ ophthalmopathy\\:\\ 0\\.015945329251288165\ \(0\)\
\-\ edema\\:\\ 0\\.015414052866270987\ \(0\)\
\-\ degree\\:\\ 0\\.015318880364518164\ \(0\)\
\-\ \\%\\:\\ 0\\.015255007908260261\ \(0\)\
\-\ lacrimal\\:\\ 0\\.014846393240848231\ \(0\)\
\-\ amyloid\\:\\ 0\\.0140808203009239\ \(0\)\
\-\ retraction\\:\\ 0\\.013812043475266178\ \(0\)\
\-\ eye\\:\\ 0\\.01371585385374456\ \(0\)\
\-\ cells\\:\\ 0\\.013111403166390296\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.013030748671660488\ \(0\)\
\-\ enlargement\\:\\ 0\\.01297411380032562\ \(0\)\
\-\ sparing\\:\\ 0\\.012953695932865125\ \(0\)\
\-\ diplopia\\:\\ 0\\.012721625070095416\ \(0\)\
\-\ most\\:\\ 0\\.012581856771224975\ \(0\)\
\-\ affects\\:\\ 0\\.012408864044349668\ \(0\)\
\-\ 85\\:\\ 0\\.0121746611125815\ \(0\)\
\-\ \\‚\\Ä\\¢\\:\\ 0\\.011992456772417509\ \(0\)\
\-\ congestion\\:\\ 0\\.01187917178726231\ \(0\)\
\-\ h\\:\\ 0\\.011474567118444357\ \(0\)\
\-\ common\\:\\ 0\\.01140952659161427\ \(0\)\
\-\ inflammatory\\:\\ 0\\.011339219174204173\ \(0\)\
\-\ sign\\:\\ 0\\.011328239164913536\ \(0\)\
\-\ fatty\\:\\ 0\\.011309928033909735\ \(0\)\
\-\ 279\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ thyrotro\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ bn\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ 1\\.98\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ 0\\.27\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ 1\\.01\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ 1\\.79\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ 15\\-28\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ werner\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ grade1\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ exophthalmometer\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ lubricating\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ eyedrops\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ ointments\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ steroids\\/radiation\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ leukocytic\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ cross\\-reactivity\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ autoantigens\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ lats\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ hygroscopic\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ interzygomatic\\:\\ 0\\.0112442837040389\ \(0\)\
\-\ painless\\:\\ 0\\.010953392466626168\ \(0\)\
\-\ fistula\\:\\ 0\\.010690167374189354\ \(0\)\
\-\ increased\\:\\ 0\\.010665738682651305\ \(0\)\
\-\ subarachnoid\\:\\ 0\\.010592039106771508\ \(0\)\
\-\ bilateral\\:\\ 0\\.010580702700583897\ \(0\)\
\-\ inh\\:\\ 0\\.010360167402304277\ \(0\)\
\-\ 78\\.7\\:\\ 0\\.010360167402304277\ \(0\)\
\-\ infundibula\\:\\ 0\\.010360167402304277\ \(0\)\
\-\ immunosuppressives\\:\\ 0\\.010360167402304277\ \(0\)\
\-\ glycoproteins\\:\\ 0\\.010360167402304277\ \(0\)\
\-\ palpebrae\\:\\ 0\\.010360167402304277\ \(0\)\
\-\ \\;\\:\\ 0\\.010333781573737722\ \(0\)\
\-\ involves\\:\\ 0\\.010130947289560988\ \(0\)\
\-\ ischemia\\:\\ 0\\.010130947289560988\ \(0\)\
\-\ vision\\:\\ 0\\.010071387687527845\ \(0\)\
\-\ margins\\:\\ 0\\.009900623701111751\ \(0\)\
\-\ opthalmopathy\\:\\ 0\\.00984299251951325\ \(0\)\
\-\ stare\\:\\ 0\\.00984299251951325\ \(0\)\
\-\ collagenous\\:\\ 0\\.00984299251951325\ \(0\)\
\-\ \\‚\\Ä\\ì\\:\\ 0\\.009810472256098208\ \(0\)\
\-\ gland\\:\\ 0\\.009284103804573134\ \(0\)\
\-\ \\(\\:\\ 0\\.00921379752862067\ \(0\)\
\-\ 1\\.25\\:\\ 0\\.009191429223893363\ \(0\)\
\-\ midpoint\\:\\ 0\\.009191429223893363\ \(0\)\
\-\ acting\\:\\ 0\\.009191429223893363\ \(0\)\
\-\ attachments\\:\\ 0\\.009191429223893363\ \(0\)\
\-\ retro\\-ocular\\:\\ 0\\.009191429223893363\ \(0\)\
\-\ diameter\\:\\ 0\\.009171333160429012\ \(0\)\
\-\ \\)\\:\\ 0\\.009101246072873789\ \(0\)\
\-\ orbitopathy\\:\\ 0\\.008958876217778626\ \(0\)\
\-\ lens\\:\\ 0\\.008958876217778626\ \(0\)\
\-\ prominent\\:\\ 0\\.008947068180013503\ \(0\)\
\-\ results\\:\\ 0\\.008799853084042466\ \(0\)\
\-\ eom\\:\\ 0\\.008762255452692836\ \(0\)\
\-\ immunoglobulins\\:\\ 0\\.008762255452692836\ \(0\)\
\-\ soluble\\:\\ 0\\.008762255452692836\ \(0\)\
\-\ levator\\:\\ 0\\.008762255452692836\ \(0\)\
\-\ reflecting\\:\\ 0\\.008762255452692836\ \(0\)\
\-\ tram\\:\\ 0\\.008762255452692836\ \(0\)\
\-\ due\\:\\ 0\\.008725550330176681\ \(0\)\
\-\ irreversible\\:\\ 0\\.008591934798835028\ \(0\)\
\-\ pressure\\:\\ 0\\.008561053341383518\ \(0\)\
\-\ \\#\\:\\ 0\\.008550220966685939\ \(0\)\
\-\ acromegaly\\:\\ 0\\.0084417013349876\ \(0\)\
\-\ tendinous\\:\\ 0\\.0084417013349876\ \(0\)\
\-\ \\<\\:\\ 0\\.008413432468116811\ \(0\)\
\-\ implicated\\:\\ 0\\.008307312922158739\ \(0\)\
\-\ chemosis\\:\\ 0\\.008185743815265469\ \(0\)\
\-\ lag\\:\\ 0\\.008185743815265469\ \(0\)\
\-\ compression\\:\\ 0\\.008160069709948791\ \(0\)\
\-\ intraconal\\:\\ 0\\.008074759916044002\ \(0\)\
\-\ exophthalmos\\:\\ 0\\.007972664625644083\ \(0\)\
\-\ thyrotoxicosis\\:\\ 0\\.007972664625644083\ \(0\)\
\-\ resolves\\:\\ 0\\.007972664625644083\ \(0\)\
\-\ human\\:\\ 0\\.007878139150958212\ \(0\)\
\-\ antigen\\:\\ 0\\.007878139150958212\ \(0\)\
\-\ 125\\:\\ 0\\.007790138039367713\ \(0\)\
\-\ hormonal\\:\\ 0\\.007790138039367713\ \(0\)\
\-\ eyelid\\:\\ 0\\.007790138039367713\ \(0\)\
\-\ fibrotic\\:\\ 0\\.007790138039367713\ \(0\)\
\-\ stretching\\:\\ 0\\.007707818497100403\ \(0\)\
\-\ 3\\:\\ 0\\.007656794107295432\ \(0\)\
\-\ \\&\\:\\ 0\\.007656601765666917\ \(0\)\
\-\ 4\\.2\\:\\ 0\\.0074886217408164\ \(0\)\
\-\ enlarged\\:\\ 0\\.007437808853020424\ \(0\)\
\-\ ft4\\:\\ 0\\.007423196620424116\ \(0\)\
\-\ mechanisms\\:\\ 0\\.007423196620424116\ \(0\)\
\-\ inferior\\:\\ 0\\.00739621520754863\ \(0\)\
\-\ plasma\\:\\ 0\\.007360964268167187\ \(0\)\
\-\ modified\\:\\ 0\\.007301627513530844\ \(0\)\
\-\ pathophysiology\\:\\ 0\\.007301627513530844\ \(0\)\
\-\ cases\\:\\ 0\\.007262272612196766\ \(0\)\
\-\ swelling\\:\\ 0\\.007262272612196766\ \(0\)\
\-\ by\\:\\ 0\\.007259545424718748\ \(0\)\
\-\ periorbital\\:\\ 0\\.007244928836782332\ \(0\)\
\-\ \\>\\:\\ 0\\.0072427742721136845\ \(0\)\
\-\ space\\:\\ 0\\.007210604609889373\ \(0\)\
\-\ extradural\\:\\ 0\\.007190643614309377\ \(0\)\
\-\ cerebri\\:\\ 0\\.007190643614309377\ \(0\)\
\-\ may\\:\\ 0\\.0071721748809877185\ \(0\)\
\-\ vascular\\:\\ 0\\.007147457316131879\ \(0\)\
\-\ measurement\\:\\ 0\\.007138574743747828\ \(0\)\
\-\ track\\:\\ 0\\.007138574743747828\ \(0\)\
\-\ disease\\:\\ 0\\.007126211944978082\ \(0\)\
\-\ ill\\:\\ 0\\.007088548323909458\ \(0\)\
\-\ maximal\\:\\ 0\\.007088548323909458\ \(0\)\
\-\ trapping\\:\\ 0\\.007088548323909458\ \(0\)\
\-\ symmetrical\\:\\ 0\\.00704041015046195\ \(0\)\
\-\ in\\:\\ 0\\.006987454071203207\ \(0\)\
\-\ medial\\:\\ 0\\.006972702840790948\ \(0\)\
\-\ superior\\:\\ 0\\.00696108085983212\ \(0\)\
\-\ often\\:\\ 0\\.006955289664590949\ \(0\)\
\-\ basic\\:\\ 0\\.006949263512729622\ \(0\)\
\-\ autoimmune\\:\\ 0\\.006949263512729622\ \(0\)\
\-\ correlate\\:\\ 0\\.006784452630739818\ \(0\)\
\-\ endocrine\\:\\ 0\\.0067463748716203266\ \(0\)\
\-\ ulceration\\:\\ 0\\.006709400972547301\ \(0\)\
\-\ neuropathy\\:\\ 0\\.006709400972547301\ \(0\)\
\-\ extraocular\\:\\ 0\\.006673468731518352\ \(0\)\
\-\ tendons\\:\\ 0\\.006638521060360042\ \(0\)\
\-\ usually\\:\\ 0\\.006619714933333569\ \(0\)\
\-\ develops\\:\\ 0\\.006604505439081776\ \(0\)\
\-\ t2wi\\:\\ 0\\.0065390803186894915\ \(0\)\
\-\ ulcers\\:\\ 0\\.00641751121179622\ \(0\)\
\-\ ethmoid\\:\\ 0\\.006360812535047708\ \(0\)\
\-\ classically\\:\\ 0\\.006360812535047708\ \(0\)\
\-\ globe\\:\\ 0\\.006333381150837296\ \(0\)\
\-\ rectus\\:\\ 0\\.006306527312574754\ \(0\)\
\-\ considerations\\:\\ 0\\.0062802272013467745\ \(0\)\
\-\ males\\:\\ 0\\.0062802272013467745\ \(0\)\
\-\ staging\\:\\ 0\\.0062802272013467745\ \(0\)\
\-\ abnormal\\:\\ 0\\.006217072041619671\ \(0\)\
\-\ spontaneously\\:\\ 0\\.006156293848727326\ \(0\)\
\-\ contents\\:\\ 0\\.006156293848727326\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.006132889335119932\ \(0\)\
\-\ fibers\\:\\ 0\\.006132889335119932\ \(0\)\
\-\ spasm\\:\\ 0\\.006109906547488965\ \(0\)\
\-\ against\\:\\ 0\\.006109906547488965\ \(0\)\
\-\ t2w\\:\\ 0\\.006109906547488965\ \(0\)\
\-\ plane\\:\\ 0\\.00608733055629075\ \(0\)\
\-\ females\\:\\ 0\\.006065147210994998\ \(0\)\
\-\ sheath\\:\\ 0\\.006000822142593351\ \(0\)\
\-\ and\\:\\ 0\\.005969686414588877\ \(0\)\
\-\ maxillary\\:\\ 0\\.005959673083641538\ \(0\)\
\-\ are\\:\\ 0\\.005943234043518376\ \(0\)\
\-\ tsh\\:\\ 0\\.0059198101454985465\ \(0\)\
\-\ measured\\:\\ 0\\.0059198101454985465\ \(0\)\
\-\ slow\\:\\ 0\\.005900336329005194\ \(0\)\
\-\ follows\\:\\ 0\\.005862258569885702\ \(0\)\
\-\ top\\:\\ 0\\.0058436376522566814\ \(0\)\
\-\ dysfunction\\:\\ 0\\.005807192024139264\ \(0\)\
\-\ ddx\\:\\ 0\\.005754404758625418\ \(0\)\
\-\ arteriovenous\\:\\ 0\\.005720389137347152\ \(0\)\
\-\ thick\\:\\ 0\\.005720389137347152\ \(0\)\
\-\ developing\\:\\ 0\\.005703715563919406\ \(0\)\
\-\ population\\:\\ 0\\.005687257139383809\ \(0\)\
\-\ determined\\:\\ 0\\.005687257139383809\ \(0\)\
\-\ remaining\\:\\ 0\\.005671008382014639\ \(0\)\
\-\ isolated\\:\\ 0\\.005671008382014639\ \(0\)\
\-\ mucosal\\:\\ 0\\.0056234683376304145\ \(0\)\
\-\ m\\:\\ 0\\.0056234683376304145\ \(0\)\
\-\ sinuses\\:\\ 0\\.005608007418584055\ \(0\)\
\-\ sarcoid\\:\\ 0\\.005592731664697938\ \(0\)\
\-\ leukemia\\:\\ 0\\.005592731664697938\ \(0\)\
\-\ adults\\:\\ 0\\.00556271827514412\ \(0\)\
\-\ factor\\:\\ 0\\.00556271827514412\ \(0\)\
\-\ nerves\\:\\ 0\\.005533394910061596\ \(0\)\
\-\ degeneration\\:\\ 0\\.005533394910061596\ \(0\)\
\-\ older\\:\\ 0\\.005490636374298021\ \(0\)\
\-\ response\\:\\ 0\\.005462906799506686\ \(0\)\
\-\ more\\:\\ 0\\.005451980380898383\ \(0\)\
\-\ progression\\:\\ 0\\.00542241101084013\ \(0\)\
\-\ elevation\\:\\ 0\\.005383161446214169\ \(0\)\
\-\ granuloma\\:\\ 0\\.005357650391741376\ \(0\)\
\-\ replacement\\:\\ 0\\.005320315720440211\ \(0\)\
\-\ night\\:\\ 0\\.005296019553385754\ \(0\)\
\-\ double\\:\\ 0\\.005272177546992701\ \(0\)\
\-\ stranding\\:\\ 0\\.005272177546992701\ \(0\)\
\-\ tb\\:\\ 0\\.0052487730333853075\ \(0\)\
\-\ suspicious\\:\\ 0\\.0052487730333853075\ \(0\)\
\-\ represents\\:\\ 0\\.005237229875834393\ \(0\)\
\-\ leading\\:\\ 0\\.005214452302620099\ \(0\)\
\-\ painful\\:\\ 0\\.005181030909260374\ \(0\)\
\-\ tissue\\:\\ 0\\.005166890786868861\ \(0\)\
\-\ therefore\\:\\ 0\\.005148462922008888\ \(0\)\
\-\ volume\\:\\ 0\\.005148462922008888\ \(0\)\
\-\ 90\\:\\ 0\\.005137789134163842\ \(0\)\
\-\ steroids\\:\\ 0\\.005127203926492036\ \(0\)\
\-\ 80\\:\\ 0\\.005127203926492036\ \(0\)\
\-\ phase\\:\\ 0\\.005127203926492036\ \(0\)\
\-\ margin\\:\\ 0\\.005127203926492036\ \(0\)\
\-\ imaging\\:\\ 0\\.005107331184835721\ \(0\)\
\-\ predominantly\\:\\ 0\\.005106293454839388\ \(0\)\
\-\ tendon\\:\\ 0\\.005085720263602292\ \(0\)\
\-\ cavernous\\:\\ 0\\.005055469591896532\ \(0\)\
\-\ be\\:\\ 0\\.005042436441367076\ \(0\)\
\-\ is\\:\\ 0\\.00502045337843505\ \(0\)\
\-\ thought\\:\\ 0\\.00501622002727057\ \(0\)\
\-\ symmetric\\:\\ 0\\.004978142268151079\ \(0\)\
\-\ 16\\:\\ 0\\.004932089966311645\ \(0\)\
\-\ it\\:\\ 0\\.004900123429931165\ \(0\)\
\-\ disorder\\:\\ 0\\.004896409032584086\ \(0\)\
\-\ carotid\\:\\ 0\\.004887642604921125\ \(0\)\
\-\ material\\:\\ 0\\.004870288456890795\ \(0\)\
\-\ fibrosis\\:\\ 0\\.004853167257487553\ \(0\)\
\-\ from\\:\\ 0\\.004846055024824792\ \(0\)\
\-\ worse\\:\\ 0\\.004827908804303651\ \(0\)\
\-\ per\\:\\ 0\\.004770847715220243\ \(0\)\
\-\ smooth\\:\\ 0\\.004770847715220243\ \(0\)\
\-\ of\\:\\ 0\\.004755257175428099\ \(0\)\
\-\ affected\\:\\ 0\\.004716230371874673\ \(0\)\
\-\ causing\\:\\ 0\\.004708615362963315\ \(0\)\
\-\ dilatation\\:\\ 0\\.004671207690648876\ \(0\)\
\-\ good\\:\\ 0\\.0046638560264693485\ \(0\)\
\-\ stage\\:\\ 0\\.004649278608326972\ \(0\)\
\-\ but\\:\\ 0\\.004649243114881473\ \(0\)\
\-\ inflammation\\:\\ 0\\.004634865910298996\ \(0\)\
\-\ intracranial\\:\\ 0\\.004606520072563396\ \(0\)\
\-\ defined\\:\\ 0\\.00459257993157846\ \(0\)\
\-\ us\\:\\ 0\\.004571951284581519\ \(0\)\
\-\ increase\\:\\ 0\\.004571951284581519\ \(0\)\
\-\ amount\\:\\ 0\\.004551650958936239\ \(0\)\
\-\ csf\\:\\ 0\\.004551650958936239\ \(0\)\
\-\ i\\:\\ 0\\.004505503437791466\ \(0\)\
\-\ levels\\:\\ 0\\.004499045144479545\ \(0\)\
\-\ line\\:\\ 0\\.004479864178453345\ \(0\)\
\-\ at\\:\\ 0\\.004430216146039412\ \(0\)\
\-\ single\\:\\ 0\\.004417934043992897\ \(0\)\
\-\ complex\\:\\ 0\\.004364656731650684\ \(0\)\
\-\ symptomatic\\:\\ 0\\.004330336000885475\ \(0\)\
\-\ complications\\:\\ 0\\.004319097952821501\ \(0\)\
\-\ necrosis\\:\\ 0\\.004302424379393756\ \(0\)\
\-\ system\\:\\ 0\\.0042914285336744865\ \(0\)\
\-\ structures\\:\\ 0\\.004196512098003462\ \(0\)\
\-\ result\\:\\ 0\\.00418135734304587\ \(0\)\
\-\ course\\:\\ 0\\.0041129227595097465\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.004070791986963214\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.004047973664577021\ \(0\)\
\-\ mm\\:\\ 0\\.004007901985707915\ \(0\)\
\-\ sinus\\:\\ 0\\.0039861721551561705\ \(0\)\
\-\ early\\:\\ 0\\.0039861721551561705\ \(0\)\
\-\ intensity\\:\\ 0\\.003939630964769516\ \(0\)\
\-\ extension\\:\\ 0\\.0038907236239561905\ \(0\)\
\-\ obstruction\\:\\ 0\\.0038436225109559122\ \(0\)\
\-\ or\\:\\ 0\\.003832357457769289\ \(0\)\
\-\ involving\\:\\ 0\\.003824499061228691\ \(0\)\
\-\ to\\:\\ 0\\.0038131081110980916\ \(0\)\
\-\ being\\:\\ 0\\.003798198950000712\ \(0\)\
\-\ long\\:\\ 0\\.0037579356005519433\ \(0\)\
\-\ does\\:\\ 0\\.003718904426510212\ \(0\)\
\-\ thickening\\:\\ 0\\.0036946741960374382\ \(0\)\
\-\ air\\:\\ 0\\.003687834982846895\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.0036844290790766414\ \(0\)\
\-\ 10\\:\\ 0\\.003674265597381263\ \(0\)\
\-\ first\\:\\ 0\\.003657504381104403\ \(0\)\
\-\ surrounding\\:\\ 0\\.003583118959648935\ \(0\)\
\-\ mr\\:\\ 0\\.003463264632584737\ \(0\)\
\-\ between\\:\\ 0\\.003454713694163576\ \(0\)\
\-\ frontal\\:\\ 0\\.0034238417531675474\ \(0\)\
\-\ normal\\:\\ 0\\.0034173787107119923\ \(0\)\
\-\ clinical\\:\\ 0\\.0033537114796760256\ \(0\)\
\-\ age\\:\\ 0\\.0033174876601330438\ \(0\)\
\-\ 6\\:\\ 0\\.003255255307876115\ \(0\)\
\-\ 5\\:\\ 0\\.0031889801306685755\ \(0\)\
\-\ infection\\:\\ 0\\.0031683884873377637\ \(0\)\
\-\ loss\\:\\ 0\\.003163857362842397\ \(0\)\
\-\ not\\:\\ 0\\.003150047631994733\ \(0\)\
\-\ level\\:\\ 0\\.0031414400862843517\ \(0\)\
\-\ s\\:\\ 0\\.0031259791672379935\ \(0\)\
\-\ changes\\:\\ 0\\.003123785683973291\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0031150492785580173\ \(0\)\
\-\ axial\\:\\ 0\\.003110703413351877\ \(0\)\
\-\ head\\:\\ 0\\.0030913282022626224\ \(0\)\
\-\ chronic\\:\\ 0\\.003070139837891581\ \(0\)\
\-\ include\\:\\ 0\\.0030575937347325083\ \(0\)\
\-\ 4\\:\\ 0\\.0030369539606875575\ \(0\)\
\-\ high\\:\\ 0\\.002982839363618387\ \(0\)\
\-\ cell\\:\\ 0\\.0029441845810988343\ \(0\)\
\-\ therapy\\:\\ 0\\.0029140826482660876\ \(0\)\
\-\ signal\\:\\ 0\\.0028738192988173195\ \(0\)\
\-\ than\\:\\ 0\\.002855929661885553\ \(0\)\
\-\ patients\\:\\ 0\\.0028208859685791145\ \(0\)\
\-\ anterior\\:\\ 0\\.0028071337037790015\ \(0\)\
\-\ for\\:\\ 0\\.0027899546504185527\ \(0\)\
\-\ on\\:\\ 0\\.0027699911187452604\ \(0\)\
\-\ metastatic\\:\\ 0\\.0027437619944082783\ \(0\)\
\-\ acute\\:\\ 0\\.002691172613656244\ \(0\)\
\-\ soft\\:\\ 0\\.002654243321420344\ \(0\)\
\-\ surgery\\:\\ 0\\.002646682480051371\ \(0\)\
\-\ upper\\:\\ 0\\.00263020472623561\ \(0\)\
\-\ into\\:\\ 0\\.0025935285305608504\ \(0\)\
\-\ without\\:\\ 0\\.0025663433244364287\ \(0\)\
\-\ other\\:\\ 0\\.002512294067222511\ \(0\)\
\-\ diagnosis\\:\\ 0\\.002502830779056658\ \(0\)\
\-\ the\\:\\ 0\\.0024687372268504607\ \(0\)\
\-\ 2\\:\\ 0\\.0023470720618756964\ \(0\)\
\-\ findings\\:\\ 0\\.0023199450711606628\ \(0\)\
\-\ treatment\\:\\ 0\\.0022061440811235802\ \(0\)\
\-\ which\\:\\ 0\\.0020346231980134548\ \(0\)\
\-\ as\\:\\ 0\\.0016486957983343465\ \(0\)\
\-\ mass\\:\\ 0\\.0015158941415147505\ \(0\)\
\-\ \\.\\:\\ 0\\.0014036806365022125\ \(0\)\
\-\ with\\:\\ 0\\.001343160184705367\ \(0\)\
\-\ this\\:\\ 0\\.0012259403231047615\ \(0\)\
\-\ no\\:\\ 0\\.0010975052942650534\ \(0\)\
\-\ a\\:\\ 0\\.0005058670941563791\ \(0\)\
